KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Revenue (2018 - 2025)

Adaptive Biotechnologies' Revenue history spans 8 years, with the latest figure at $71.7 million for Q4 2025.

  • For Q4 2025, Revenue rose 51.04% year-over-year to $71.7 million; the TTM value through Dec 2025 reached $277.0 million, up 54.77%, while the annual FY2025 figure was $277.0 million, 54.77% up from the prior year.
  • Revenue for Q4 2025 was $71.7 million at Adaptive Biotechnologies, down from $94.0 million in the prior quarter.
  • Across five years, Revenue topped out at $94.0 million in Q3 2025 and bottomed at $7.7 million in Q2 2023.
  • The 5-year median for Revenue is $43.4 million (2022), against an average of $46.2 million.
  • The largest annual shift saw Revenue plummeted 82.36% in 2023 before it skyrocketed 460.91% in 2024.
  • A 5-year view of Revenue shows it stood at $37.9 million in 2021, then skyrocketed by 45.53% to $55.2 million in 2022, then decreased by 17.05% to $45.8 million in 2023, then grew by 3.66% to $47.5 million in 2024, then soared by 51.04% to $71.7 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Revenue are $71.7 million (Q4 2025), $94.0 million (Q3 2025), and $58.9 million (Q2 2025).